SCHEMBL22509697

SCHEMBL22509697

Cc1ccc2cc(F)c(N)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NCK1 P16333 1/20 0.48
BACE1 P56817 1/20 0.48
CYP1A2 P05177 4/20 0.48
ALDH1A1 P00352 6/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 2/20 0.46
GAA P10253 2/20 0.46
KMT2A Q03164 4/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 3/20 0.42
MAPT P10636 2/20 0.42
MAPK1 P28482 1/20 0.42
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
NQO2 P16083 1/20 0.39
CYP2A6 P11509 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 1/20 0.38
ESR1 P03372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30908485 1.00 NCK1 (0.48) NCK1BACE1CYP1A2ALDH1A1LMNA
SCHEMBL22509690 0.85 NCK1 (0.53) NCK1BACE1CYP1A2ALDH1A1KMT2A
SCHEMBL22509810 0.80 CYP1A2 (0.52) NCK1BACE1CYP1A2ALDH1A1LMNA
SCHEMBL30908292 0.77 KMT2A (0.59) NCK1BACE1CYP1A2ALDH1A1LMNA
SCHEMBL18571529 0.77 BACE1 (0.55) BACE1CYP1A2ALDH1A1LMNAKMT2A
SCHEMBL22509740 0.77 KMT2A (0.50) NCK1BACE1CYP1A2ALDH1A1LMNA
SCHEMBL18571743 0.77 NCK1 (0.48) NCK1BACE1CYP1A2ALDH1A1LMNA
SCHEMBL24254157 0.77 NPC1 (0.42) BACE1ALDH1A1LMNAPOLBGAA
SCHEMBL22521405 0.77 ALOX5AP (0.41) BACE1ALDH1A1LMNAGAAKMT2A
SCHEMBL22509693 0.74 NCK1 (0.46) NCK1BACE1CYP1A2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024074611-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2024-04-11 WO disclosed
WO-2020205867-A1 COMPOUNDS TARGETING PRMT5 ALIGOS THERAPEUTICS, INC. (US) 2020-10-08 WO disclosed